June 19, 2013

Germany's Merck suffers setback with cancer drug

BY: AP Staff Writer DECEMBER 19, 2012 | MODIFIED: DECEMBER 19, 2012 AT 7:45 AM
Leave a comment

BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.

The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.

Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.

The company is a separate entity from Merck & Co., which is based in the U.S.

View article comments Leave a comment

More from washingtonexaminer.com

From the Weekly Standard

  • June 17, 1953

    Today, speaking at the Brandenburg Gate, President Obama paid appropriate tribute to the brave East Germans who rebelled 60 years ago against Communist dictatorship:

    Read More...
  • Frack to the Future

    Williston, N.D.

    Read More...
  • Downsize Ike

    The beleaguered Eisenhower Memorial Commission holds its next public gathering later this month, and before its members duck-walk into the hearing room, huddled in a hoplite phalanx against a...

    Read More...